Evaluation of RC28-E Injection in Wet Age-related Macular Degeneration

Wet Age-Related Macular Degeneration Clinical Trial

Official title:

A Nonrandomized, Open-label Study to Evaluate the Safety and Pharmacokinetics of Multiple Administration of RC28-E Injection (a Chimeric Decoy Receptor Trap Fusion Protein by Dual Blockage of VEGF and FGF-2) in Subjects With Wet Age-Related Macular Degeneration

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04270669
• Other study ID #: 28C001
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: April 15, 2020
• Est. completion date: October 29, 2021

Study information

• Verified date: January 2022
• Source: RemeGen Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a non-randomized, open-label, multicenter, 48-week study to investigate the efficacy, safety and pharmacokinetics of RC28-E injection in the treatment of patients with wet age-related macular degeneration by multiple administration.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 37
• Est. completion date: October 29, 2021
• Est. primary completion date: October 29, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years to 80 Years

Eligibility

Inclusion Criteria:

A patient must meet the following criteria to be eligible for inclusion in the study:

1. Sign the consent form, willing and able to comply with clinic visits and study-related procedures;

2. Be diagnosed as wet age-related macular degeneration, choroid neovascularization (CNV) in the macular, the study eye is not treated or accepted any treatment 3 months prior to the baseline period, and still had active lesions with a diagnostic criteria according to the 2013 edition of Clinical pathway of age-related macular degeneration in China, the active CNV conforms to any item can be in the following three: New bleeding; OCT shows intraretinal fluid or subretinal fluid; Fundus angiography revealed fluorescein leakage;

3. Aged 50 years to 80 years, male or female;

4. BCVA ETDRS letters score of 73 to 34 in the study eye.

Exclusion Criteria:

A patient who meets any of the following criteria will be excluded from the study:

1. The study eye had vitreous hemorrhage within 2 months before screening;

2. The study eye had scars or atrophy involving the fovea which indicating severe irreversible visual impairment;

3. The study eye had significant refractive media opacity, including cataract, may interfere with visual assessment;;

4. The study eye had pseudoexfoliation syndrome, central retinal vein occlusion, intraocular hemorrhage resulting in decreased vision, rhegmatogenous retinal detachment, macular hole, choroidal neovascularization (CNV) for any reason other than wAMD (such as vascular striation, ocular histoplasmosis, pathological myopia, trauma, etc.);

5. The study eye had subretinal or intra-retinal bleeding with bleeding area = 50% of the total lesion area, or subfoveal bleeding with bleeding area was =4 optic disc areas;

6. The study eye had significant afferent pupillary defect;

7. The study eye was aphakia (excluding artificial lens);

8. The study eye was treated with local/grid laser photocoagulation in macular within 3 months prior to baseline;

9. The study eye had received the following intraocular surgery or laser treatment in macular (such as macular transposition, glaucoma filtrating surgery, transpupillary thermotherapy, vitrectomy, optic neurotomy, etc.); However, subjects which had received verteporfin-photodynamic therapy, cataract surgery, and neodymium yttrium aluminum garnet (YAG) capsulotomy in the study eye more than 3 months prior to baseline is eligible for inclusion;

10. Intraocular pressure in the study eye was=25mmHg despite medication treatment;

11. Either eye had active ocular infection/inflammation during the screening period, such as conjunctivitis, keratitis, scleritis, blepharitis, endophthalmitis and uveitis;

12. The visual acuity of any eye is less than 19 letters (by ETDRS chart);

13. Either eye or systemic had received anti-angiogenic therapy within 3 months prior to baseline visit (e.g. aflibercept, ranibizumab, conbercept, etc.);

14. Either eye that received IVT corticosteroids (e.g. triamcinolone acetonide, dexamethasone) within 6 months prior to baseline visit or received periocular injection of corticosteroids within 1 month prior to screening;

15. Allergy to sodium fluorescein, indocyanine green, therapeutic or diagnostic protein products, and allergic =2 drugs and/or non-drug factors;

16. Uncontrolled diabetes mellitus (HbA1c =7%) and/or diabetic patients with diabetic retinopathy;

17. Uncontrolled hypertension (defined as those who received the best treatment regimen, > 180mmHg systolic was measured once, > 160mmHg systolic or > 100mmHg diastolic was measured twice in succession);

18. History of cardiovascular and cerebrovascular events within 6 months of screening visit: myocardial infarction, unstable angina pectoris, ventricular arrhythmias, New York heart association grade II + heart failure, stroke, etc.;

19. History of surgery within 1 month before screening, or have unhealed wounds, fractures, etc.;

20. Uncontrolled clinical disease (such as malignant tumors, severe psychiatric, neurological, cardiovascular, respiratory disease or other systemic diseases);

21. Platelets count =100×10^9/L, thrombin time and prothrombin time exceeding more than 3 second above the upper limit of the normal range (The normal range of the clinical trial institution was taken as the standard); with active disseminated intravascular coagulation or significant bleeding tendency prior to screening; using anticoagulants or antiplatelet aggregation drugs in addition to aspirin/NASIDs within 14 days before screening;

22. Pregnant or lactating women. Subjects of child-bearing age (male and female) do not agree to use effective contraception (such as intrauterine devices, acyeterion or condoms) throughout the study period and 30 days after the end of the visit;

23. Those who participated in clinical trials for 3 months or 5 half-lives of the investigational product (the longer the time) before the baseline period;

24. Those who considered unsuitable for enrollment by investigator.

Related Conditions & MeSH terms

• Macular Degeneration
• Wet Age-Related Macular Degeneration

Intervention

Biological:
• intravitreal injection of RC28-E 0.5mg
The patient received one treatment of RC28-E 0.5mg in the test group
• intravitreal injection of RC28-E 1.0mg
The patient received one treatment of RC28-E 1.0mg in the test group
• intravitreal injection of RC28-E2.0mg
The patient received one treatment of RC28-E 2.0mg in the test group

Locations

Country	Name	City	State
China	Beijing Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
RemeGen Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean change of BCVA from baseline at 12 week;	Measurement of visual acuity with Early Treatment Diabetic Retinopathy Study (ETDRS) charts.	Baseline, Week 12
Primary	Mean change of BCVA from baseline at 48 week;	Measurement of visual acuity with Early Treatment Diabetic Retinopathy Study (ETDRS) charts.	Baseline, Week 48
Primary	Incidence and severity of AEs	To evaluate the safety of multiple intravitreal injection of RC28-E of each group.)	Baseline up to Week 48
Secondary	The pharmacokinetic (PK) characteristics of RC28-E;	Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method. These data were analyzed using a noncompartmental pharmacokinetic (PK) method.	Baseline up to Week 48
Secondary	Frequency of administration RC28-E within 48 weeks;	Number of intravitreal injections	Baseline up to Week 48
Secondary	Mean change of BCVA from baseline at Protocol Specified Time-Points.	Measurement of visual acuity with Early Treatment Diabetic Retinopathy Study (ETDRS) charts.	Baseline up to Week 48